Allopurinol in dermatology
Journal
American Journal of Clinical Dermatology
Journal Volume
11
Journal Issue
4
Pages
225-232
Date Issued
2010
Author(s)
Yeh T.-Y.
Abstract
Off-label use is common in dermatology, and is inevitable for rare cutaneous diseases such as perforating dermatosis. Allopurinol is traditionally considered to be a drug for hyperuricemia only, but the recent demonstration of its efficacy in congestive heart failure has spurred renewed interest in its application in other clinical specialties. In dermatology, allopurinol is best known for its severe cutaneous adverse reactions. Recent genomic studies conducted in Taiwan have discovered useful HLA markers for determining the susceptibility of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with allopurinol.Allopurinol has also been used in a number of dermatologic disorders including acquired reactive perforating collagenosis, sarcoidosis, psoriasis and granulomas caused by methacrylate microspheres, silicon and tattoos. Allopurinol may express its therapeutic effects via its antioxidation or anti-inflammatory properties, or its ability to improve vascular function. ? 2010 Adis Data Information.
SDGs
Other Subjects
allopurinol; aminophylline; amoxicillin; ampicillin; ascomycin; azathioprine; benazepril; captopril; chlorpropamide; corticosteroid; cyclophosphamide; cyclosporin; dicoumarol; didanosine; dipeptidyl carboxypeptidase inhibitor; hydrochlorothiazide; lisinopril; meglumine antimonate; mercaptopurine; minocycline; oxipurinol; poly(methyl methacrylate); silicon; sulfinpyrazone; tacrolimus; theophylline; thiazide diuretic agent; tolbutamide; warfarin; xanthine oxidase; abdominal surgery; acute hemorrhagic pancreatitis; antiinflammatory activity; antioxidant activity; autoimmune skin disease; Behcet disease; cardiovascular function; cell function; chronic pancreatitis; chronic prostatitis; collagen disease; congestive heart failure; disease predisposition; DRESS syndrome; drug blood level; drug dose increase; drug effect; drug efficacy; drug indication; drug mechanism; drug metabolism; drug monitoring; drug safety; endothelium cell; enzyme inhibition; esophagus stricture; face edema; folliculitis; foot ulcer; foreign body granuloma; gout; granuloma; granuloma annulare; heart failure; herpes labialis; HLA system; human; hyperuricemia; kyrle disease; maculopapular rash; nerve function; off label drug use; pityriasis rosea; priority journal; psoriasis; pyoderma gangrenosum; rash; reactive perforating collagenosis; review; sarcoidosis; scleroderma; skin disease; skin granuloma; skin leishmaniasis; skin manifestation; skin toxicity; Stevens Johnson syndrome; toxic epidermal necrolysis; Allopurinol; Animals; Dermatologic Agents; Drug Eruptions; Drug Interactions; Epidermal Necrolysis, Toxic; Gout Suppressants; Humans; Off-Label Use; Skin Diseases; Stevens-Johnson Syndrome
Type
review